Literature DB >> 26884600

ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases.

C Leah B Kline1, A Pieter J Van den Heuvel2, Joshua E Allen3, Varun V Prabhu1, David T Dicker1, Wafik S El-Deiry4.   

Abstract

ONC201 (also called TIC10) is a small molecule that inactivates the cell proliferation- and cell survival-promoting kinases Akt and ERK and induces cell death through the proapoptotic protein TRAIL. ONC201 is currently in early-phase clinical testing for various malignancies. We found through gene expression and protein analyses that ONC201 triggered an increase in TRAIL abundance and cell death through an integrated stress response (ISR) involving the transcription factor ATF4, the transactivator CHOP, and the TRAIL receptor DR5. ATF4 was not activated in ONC201-resistant cancer cells, and in ONC201-sensitive cells, knockdown of ATF4 or CHOP partially abrogated ONC201-induced cytotoxicity and diminished the ONC201-stimulated increase in DR5 abundance. The activation of ATF4 in response to ONC201 required the kinases HRI and PKR, which phosphorylate and activate the translation initiation factor eIF2α. ONC201 rapidly triggered cell cycle arrest, which was associated with decreased abundance of cyclin D1, decreased activity of the kinase complex mTORC1, and dephosphorylation of the retinoblastoma (Rb) protein. The abundance of X-linked inhibitor of apoptosis protein (XIAP) negatively correlated with the extent of apoptosis in response to ONC201. These effects of ONC201 were independent of whether cancer cells had normal or mutant p53. Thus, ONC201 induces cell death through the coordinated induction of TRAIL by an ISR pathway.
Copyright © 2016, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26884600      PMCID: PMC4968406          DOI: 10.1126/scisignal.aac4374

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  45 in total

1.  Structure of the double-stranded RNA-binding domain of the protein kinase PKR reveals the molecular basis of its dsRNA-mediated activation.

Authors:  S Nanduri; B W Carpick; Y Yang; B R Williams; J Qin
Journal:  EMBO J       Date:  1998-09-15       Impact factor: 11.598

2.  NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase.

Authors:  M Zamanian-Daryoush; T H Mogensen; J A DiDonato; B R Williams
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

3.  Small-molecule activation of the TRAIL receptor DR5 in human cancer cells.

Authors:  Gelin Wang; Xiaoming Wang; Hong Yu; Shuguang Wei; Noelle Williams; Daniel L Holmes; Randal Halfmann; Jacinth Naidoo; Lai Wang; Lin Li; She Chen; Patrick Harran; Xiaoguang Lei; Xiaodong Wang
Journal:  Nat Chem Biol       Date:  2012-12-23       Impact factor: 15.040

4.  An integrated stress response regulates amino acid metabolism and resistance to oxidative stress.

Authors:  Heather P Harding; Yuhong Zhang; Huiquing Zeng; Isabel Novoa; Phoebe D Lu; Marcella Calfon; Navid Sadri; Chi Yun; Brian Popko; Richard Paules; David F Stojdl; John C Bell; Thore Hettmann; Jeffrey M Leiden; David Ron
Journal:  Mol Cell       Date:  2003-03       Impact factor: 17.970

5.  Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.

Authors:  Varun V Prabhu; Joshua E Allen; David T Dicker; Wafik S El-Deiry
Journal:  Cancer Res       Date:  2015-02-20       Impact factor: 12.701

Review 6.  Roles of the translation initiation factor eIF2α serine 51 phosphorylation in cancer formation and treatment.

Authors:  Antonis E Koromilas
Journal:  Biochim Biophys Acta       Date:  2014-12-11

7.  Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis.

Authors:  Min Lu; David A Lawrence; Scot Marsters; Diego Acosta-Alvear; Philipp Kimmig; Aaron S Mendez; Adrienne W Paton; James C Paton; Peter Walter; Avi Ashkenazi
Journal:  Science       Date:  2014-07-04       Impact factor: 47.728

Review 8.  Pharmacological targeting of endoplasmic reticulum stress signaling in cancer.

Authors:  Axel H Schönthal
Journal:  Biochem Pharmacol       Date:  2012-09-20       Impact factor: 5.858

9.  Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.

Authors:  Joshua E Allen; Gabriel Krigsfeld; Patrick A Mayes; Luv Patel; David T Dicker; Akshal S Patel; Nathan G Dolloff; Evangelos Messaris; Kimberly A Scata; Wenge Wang; Jun-Ying Zhou; Gen Sheng Wu; Wafik S El-Deiry
Journal:  Sci Transl Med       Date:  2013-02-06       Impact factor: 17.956

10.  Translation termination efficiency modulates ATF4 response by regulating ATF4 mRNA translation at 5' short ORFs.

Authors:  Hayet Ait Ghezala; Béatrice Jolles; Samia Salhi; Katia Castrillo; Wassila Carpentier; Nicolas Cagnard; Alain Bruhat; Pierre Fafournoux; Olivier Jean-Jean
Journal:  Nucleic Acids Res       Date:  2012-08-16       Impact factor: 16.971

View more
  82 in total

1.  Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.

Authors:  Isabel Arrillaga-Romany; Yazmin Odia; Varun V Prabhu; Rohinton S Tarapore; Krystal Merdinger; Martin Stogniew; Wolfgang Oster; Joshua E Allen; Minesh Mehta; Tracy T Batchelor; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

2.  ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.

Authors:  Marie D Ralff; Christina L B Kline; Ozan C Küçükkase; Jessica Wagner; Bora Lim; David T Dicker; Varun V Prabhu; Wolfgang Oster; Wafik S El-Deiry
Journal:  Mol Cancer Ther       Date:  2017-04-19       Impact factor: 6.261

3.  Small molecule ONC201 inhibits HIV-1 replication in macrophages via FOXO3a and TRAIL.

Authors:  Runze Zhao; Yuju Li; Santhi Gorantla; Larisa Y Poluektova; Hai Lin; Fengtong Gao; Hongyun Wang; Jeffrey Zhao; Jialin C Zheng; Yunlong Huang
Journal:  Antiviral Res       Date:  2019-05-31       Impact factor: 5.970

4.  Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.

Authors:  Jessica Wagner; Christina Leah Kline; Marie D Ralff; Avital Lev; Amriti Lulla; Lanlan Zhou; Gary L Olson; Bhaskara Rao Nallaganchu; Cyril H Benes; Joshua E Allen; Varun V Prabhu; Martin Stogniew; Wolfgang Oster; Wafik S El-Deiry
Journal:  Cell Cycle       Date:  2017-05-10       Impact factor: 4.534

5.  Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.

Authors:  Varun V Prabhu; Neel S Madhukar; Coryandar Gilvary; C Leah B Kline; Sophie Oster; Wafik S El-Deiry; Olivier Elemento; Faye Doherty; Alexander VanEngelenburg; Jessica Durrant; Rohinton S Tarapore; Sean Deacon; Neil Charter; Jinkyu Jung; Deric M Park; Mark R Gilbert; Jessica Rusert; Robert Wechsler-Reya; Isabel Arrillaga-Romany; Tracy T Batchelor; Patrick Y Wen; Wolfgang Oster; Joshua E Allen
Journal:  Clin Cancer Res       Date:  2018-12-17       Impact factor: 12.531

Review 6.  Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma.

Authors:  Kyle Wierzbicki; Karthik Ravi; Andrea Franson; Amy Bruzek; Evan Cantor; Micah Harris; Morgan J Homan; Bernard L Marini; Abed Rahman Kawakibi; Ramya Ravindran; Rodrigo Teodoro; Viveka Nand Yadav; Carl Koschmann
Journal:  Curr Oncol Rep       Date:  2020-02-06       Impact factor: 5.075

7.  Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.

Authors:  Jessica Wagner; C Leah Kline; Lanlan Zhou; Kerry S Campbell; Alexander W MacFarlane; Anthony J Olszanski; Kathy Q Cai; Harvey H Hensley; Eric A Ross; Marie D Ralff; Andrew Zloza; Charles B Chesson; Jenna H Newman; Howard Kaufman; Joseph Bertino; Mark Stein; Wafik S El-Deiry
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

8.  Metabolic Reprogramming by Dual AKT/ERK Inhibition through Imipridones Elicits Unique Vulnerabilities in Glioblastoma.

Authors:  Chiaki T Ishida; Yiru Zhang; Elena Bianchetti; Chang Shu; Trang T T Nguyen; Giulio Kleiner; Maria J Sanchez-Quintero; Catarina M Quinzii; Mike-Andrew Westhoff; Georg Karpel-Massler; Varun V Prabhu; Joshua E Allen; Markus D Siegelin
Journal:  Clin Cancer Res       Date:  2018-07-23       Impact factor: 12.531

9.  Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality.

Authors:  Jo Ishizawa; Sarah F Zarabi; R Eric Davis; Ondrej Halgas; Takenobu Nii; Yulia Jitkova; Ran Zhao; Jonathan St-Germain; Lauren E Heese; Grace Egan; Vivian R Ruvolo; Samir H Barghout; Yuki Nishida; Rose Hurren; Wencai Ma; Marcela Gronda; Todd Link; Keith Wong; Mark Mabanglo; Kensuke Kojima; Gautam Borthakur; Neil MacLean; Man Chun John Ma; Andrew B Leber; Mark D Minden; Walid Houry; Hagop Kantarjian; Martin Stogniew; Brian Raught; Emil F Pai; Aaron D Schimmer; Michael Andreeff
Journal:  Cancer Cell       Date:  2019-05-02       Impact factor: 31.743

Review 10.  Developing TRAIL/TRAIL death receptor-based cancer therapies.

Authors:  Xun Yuan; Ambikai Gajan; Qian Chu; Hua Xiong; Kongming Wu; Gen Sheng Wu
Journal:  Cancer Metastasis Rev       Date:  2018-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.